Molecular Construction and Anti-Bladder Cancer Study of Novel TOP1/PARP1 Dual-Target Inhibitors

Authors

D H Zhang
Zujie Mao (ORCID: https://orcid.org/0000-0002-9373-4876)
Jin Liu (ORCID: https://orcid.org/0000-0003-1063-9791)
Wenchao Wang (ORCID: https://orcid.org/0000-0003-0757-4878)
Hong Wang (ORCID: https://orcid.org/0000-0003-0058-060X)
Qi Zhang (ORCID: https://orcid.org/0000-0002-6096-0690)
Qingyong Li (ORCID: https://orcid.org/0000-0003-1492-3909)
Li Li (ORCID: https://orcid.org/0009-0003-4636-9487)
Facai Zhang
Liu Y
Dan Li
Shuai Meng
Qi Zhang
Xuyang Shi

Institutions

QT Ultrasound (United States) (US)
Ministry of Education (KR)
Zhejiang Provincial People's Hospital (CN)
Hangzhou Medical College (CN)
Zhejiang University of Technology (CN)

Publication Details

Journal: Journal of Medicinal Chemistry
Published: 2026-07-27
DOI: https://doi.org/10.1021/acs.jmedchem.6c01714
Primary Topic: PARP inhibition in cancer therapy
Type: article
Field-Weighted Citation Impact: 0.00

Funders

China Postdoctoral Science Foundation
Zhejiang University of Technology
National Key Research and Development Program of China
Natural Science Foundation of Zhejiang Province

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Molecular Construction and Anti-Bladder Cancer Study of Novel TOP1/PARP1 Dual-Target Inhibitors

D H Zhang, Zujie Mao, Jin Liu, Wenchao Wang et al.

Jul 27, 2026

Journal of Medicinal Chemistry

PARP inhibition in cancer therapy

article

Molecular Construction and Anti-Bladder Cancer Study of Novel TOP1/PARP1 Dual-Target Inhibitors

D H Zhang, Zujie Mao, Jin Liu, Wenchao Wang, Hong Wang, Qi Zhang, Qingyong Li, Li Li, Facai Zhang, Liu Y, Dan Li, Shuai Meng, Qi Zhang, Xuyang Shi

July 27, 2026article en

Abstract

No abstract available for this paper.

Journal of Medicinal Chemistry

QT Ultrasound (United States) (US), Ministry of Education (KR), Zhejiang Provincial People's Hospital (CN), Hangzhou Medical College (CN), Zhejiang University of Technology (CN)

China Postdoctoral Science Foundation, Zhejiang University of Technology, National Key Research and Development Program of China, Natural Science Foundation of Zhejiang Province

Good health and well-being

Openalex Percentile: Top 12%

PARP inhibition in cancer therapy

DOI Source OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Molecular Construction and Anti-Bladder Cancer Study of Novel TOP1/PARP1 Dual-Target Inhibitors — D H Zhang, Zujie Mao, et al. · Journal of Medicinal Chemistry (2026) | TGRS Research Map | TGRS